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ABSTRACT
Objective: To compare the effectiveness of pain
exposure physical therapy (PEPT) with conventional
treatment in patients with complex regional pain
syndrome type 1 (CRPS-1) in a randomised controlled
trial with a blinded assessor.
Setting: The study was conducted at a level 1 trauma
centre in the Netherlands.
Participants: 56 adult patients with CRPS-1
participated. Three patients were lost to follow-up.
Interventions: Patients received either PEPT in a
maximum of five treatment sessions, or conventional
treatment following the Dutch multidisciplinary
guideline.
Measurements: Outcomes were assessed at baseline
and at 3, 6 and 9 months after randomisation. The
primary outcome measure was the Impairment level
Sum Score—Restricted Version (ISS-RV), consisting of
visual analogue scale for pain (VAS-pain), McGill Pain
Questionnaire, active range of motion (AROM) and skin
temperature. Secondary outcome measures included
Pain Disability Index (PDI); muscle strength; Short
Form 36 (SF-36); disability of arm, shoulder and hand;
Lower Limb Tasks Questionnaire (LLTQ); 10 m walk
test; timed up-and-go test (TUG) and EuroQol-5D.
Results: The intention-to-treat analysis showed a
clinically relevant decrease in ISS-RV (6.7 points for
PEPT and 6.2 points for conventional treatment), but
the between-group difference was not significant (0.96,
95% CI −1.56 to 3.48). Participants allocated to PEPT
experienced a greater improvement in AROM (between-
group difference 0.51, 95% CI 0.07 to 0.94; p=0.02).
The per protocol analysis showed larger and significant
between-group effects on ISS-RV, VAS-pain, AROM,
PDI, SF-36, LLTQ and TUG.
Conclusions: We cannot conclude that PEPT is
superior to conventional treatment for patients with
CRPS-1. Further high-quality research on the effects of
PEPT is warranted given the potential effects as
indicated by the per protocol analysis.
Trial registration numbers: NCT00817128 and
NTR 2090.
INTRODUCTION
Complex regional pain syndrome type 1
(CRPS-1) is deﬁned by the International
Association for the Study of Pain (IASP) as a
pain syndrome that can develop after phys-
ical injury and is characterised by pain, in
combination with sensory, autonomic, motor
and/or trophic changes. The symptoms
exceed the expected clinical course of the
inciting event.1
CRPS-1 is seen as a multifactorial disorder
that requires a multidisciplinary approach.
The variability in the activation of the three
major pathophysiological pathways (aberrant
inﬂammatory mechanisms, vasomotor dys-
function and maladaptive neuroplasticity)
involved in CRPS cause the clinical hetero-
geneity.2 Different stages have been identi-
ﬁed,2 3 and over time, clinical features
spread and may even occur in the opposite
or ipsilateral limb.4 5
To date, there are many uncertainties
regarding the most optimal way of managing
this disabling disorder, which in many cases
appears to be therapy resistant. Recent sys-
tematic reviews show that there is still insufﬁ-
cient evidence for the effectiveness of most
therapies.6 7 The Cochrane systematic review
Strengths and limitations of this study
▪ The trial was prospectively registered and fol-
lowed published protocol.
▪ Patients were randomised, allocation was con-
cealed and the assessor was blinded.
▪ Low inclusion rate, underpowered trial.
▪ Substantial number of patients switched.
▪ Ten patients in the pain exposure physical
therapy (PEPT) group received some form of
medication or other conventional treatment.
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from 2013 concluded that there is low-quality evidence
for many treatment modalities such as the use of bispho-
sphonates, calcitonin or a daily course of intravenous
ketamine; graded motor imagery; and physical or occu-
pational therapy. The review authors generally identiﬁed
a critical lack of high-quality evidence for the effective-
ness of most therapies.7
Despite the lack of high-quality evidence, the Dutch
national multidisciplinary clinical guideline for the treat-
ment of CRPS-1 was issued in 2006.8 Treatment recom-
mendations in this guideline include pharmacological
interventions aimed primarily at decreasing pain com-
bined with physical and/or occupational therapy. This
therapy is focused on controlling pain and other symp-
toms, using mild exposure, and increasing the capacity
step by step in a pain-contingent manner.
Pharmacological treatment includes the use of analge-
sics in a step-up procedure in accordance with the WHO
pain ladder, free radical scavengers including dimethyl
sulfoxide 50% ointment (DMSO) and N-acetylcysteine,
calcium channel blockers and ketanserin. Patients pre-
senting with allodynia or hyperalgesia are given gaba-
pentin, amitriptyline or carbamazepine. Dystonia,
myoclonia and muscle spasms are treated with baclofen,
diazepam or clonazepam. In the case of cold skin, the
anaesthesiologist will prescribe vasodilating drugs such
as verapamil, ketensin and pentoxifylline. In case of
insufﬁcient clinical effect, sympathetic blockade or
spinal cord stimulation can be considered.8
In contrast to the biomedical approach as advocated in
the guideline, the attention of the research community
has shifted over past decades towards a behavioural para-
digm for the management of benign chronic pain disor-
ders. A widely used model in treatment of patients with
chronic pain is the fear-avoidance model of Vlaeyen.9
When injury leads to pain, rest and avoidance of move-
ment may be adaptive in the acute phase, but in the
longer term, this ‘protective’ responding is no longer func-
tional and may paradoxically worsen the problem.10 11
Decreased motor activity can lead to changes in cortical
representation zones,12 which have been identiﬁed in
patients with CRPS-1.13 Movements are more effortful, and
unsuccessful motor attempts lead to compensatory behav-
iour. Unpleasant and unsuccessful experiences, in combin-
ation with pain increase, lead to increased pain-avoidance
behaviour, which causes so-called learnt non-use.12
In order to overcome the hypothesised learnt non-use,
some treatment approaches apply a well-known and
accepted strategy in psychology: graded exposure to
fearful stimuli in order to overcome fear and avoidance
behaviour. Patients with CRPS-1 are instructed to use
their affected limb step by step, using positive reinforce-
ment and under explanation that motor activities are
not harmful but rather enhance recovery.
A more direct alternative is pain exposure physical
therapy (PEPT, table 1).14 15 PEPT is not similar to
graded exposure, as PEPT is neither limited to patients
with high levels of fear nor uses a strict hierarchy of
avoided activities to which patients need to be exposed
gradually, as is typical for graded exposure. In PEPT,
patients are directly exposed to painful stimuli (ie, activ-
ities). They are stressed to regain their normal daily
Table 1 Description of interventions according to the TIDieR checklist
Pain exposure physical therapy Conventional treatment
Why Pain is a false warning sign
Rapidly regaining functional activity, despite levels of
pain
Pain is a sign of dysfunction
Pain contingent, improving functional activity while
controlling pain
What Exposure to painful movements and activities;
No medication, no TENS, no walking aids, splints or
bandages;
Self-massage, ‘forced’ use, progressive-loading
exercises, muscle strength training, joint mobility
exercises;
Information and education about CRPS-1, PEPT
and the role of chronic pain as a false warning sign;
Internal locus of control
Dependent of pain limits;
Medication (analgesics, free radical scavengers, Ca2+
channel blockers, etc), TENS, walking aids, splints,
bandages;
Mild exposure, progressive-loading exercises, muscle
strength training, joint mobility exercises;
Information and education about CRPS-1 and the role
of pain as a protective response and a sign of
dysfunction;
External locus of control
Who
provided
Two physical therapists;
Partner as a ‘home coach’
Anaesthesiologist, physical therapist, rehabilitation
physician
How Face-to-face, individually, explicit home exercises
and functioning in activities of daily living
Face-to-face, individually
Where PT department, continuously in daily life Anaesthesiology department, PT department
How much Maximum five sessions of 40 min No predefined limits, on average 15–20 sessions
Tailoring Adapted to individual competencies and daily life
requirements
Adapted to levels of pain
CRPS-1, complex regional pain syndrome type 1; PEPT, pain exposure physical therapy; PT, physical therapy; TENS, transcutaneous
electrical nerve stimulation; TIDieR, Template for Intervention Description and Replication.
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activities as soon as possible, without the use of medica-
tion, and are instructed to ignore their pain. It is
explained to them that pain in itself has become a ‘false
warning sign’ due to long-lasting functional disturbances
in the affected limb. On the basis of the history taking
and observations during assessment, the intervention is
adapted to the individual patient. During the ﬁrst assess-
ment, patients, along with their partners, set their per-
sonal goals for treatment. They receive detailed
information about the condition, the working mechan-
ism of pain and pain-related avoidance behaviour, and
the rationale and content of PEPT. The therapists inform
the patients that, although understanding the pain, they
will not respond to it: they will ignore both verbal and
non-verbal expressions of pain during treatment.
Because of improved function, the pain will eventually
diminish. All medication aimed at CRPS-1, including
analgesics, is stopped and use of crutches and other
walking aids, splints and bandages is discouraged.
Patients learn how to decrease skin sensitivity for touch
and pressure by performing self-massage and ‘forced’ use
of the affected extremity in daily activities. The tailored
progressive-loading exercises focus on speciﬁc daily activ-
ities, using muscle strength training and joint mobility
exercises, both passive and active. The patients perform
the exercises at home and incorporate them in their daily
life using regular daily schedules. The physical therapists
act mainly as instructors and coaches, and conﬁrm and
reward progression with positive feedback. They instruct
the partners to change their protective and curative role
into a facilitating, motivating and coaching role, remov-
ing barriers without taking over. The partners have to
ignore the pain behaviour of the patients during the
treatment sessions and home exercises. The key to
success of PEPT is internal motivation and adherence.14
It has already been shown that PEPT is a promising
treatment for patients with CRPS-1.14 15
Objective
The objective of the current study is to evaluate the
effectiveness of this novel CRPS-1 treatment with PEPT
compared with the currently best available care in the
Netherlands, which is treatment according to the Dutch
multidisciplinary guideline for CRPS-1.8
In accordance with the TIDieR (Template for
Intervention Description and Replication) checklist,16
descriptions of both interventions under study can be
found in table 1.
METHODS
Design overview
We designed this trial as a randomised controlled trial
with blinding of the assessor. The assessor (TT) con-
ducted the measurements at baseline and at 3, 6 and
9 months follow-up. The experimental and control inter-
ventions were performed by two different teams. The
study protocol and rationale of both treatment strategies
have been published elsewhere.17
We applied the consolidated standards of reporting
trials (CONSORT) guidelines. This trial was prospect-
ively registered at http://www.clinicaltrials.gov, NCT0081
7128, and at http://www.trialregister.nl, NTR 2090.
Setting and participants
The trial was conducted in a university hospital, a level 1
trauma centre in the Netherlands. Approximately 150
new adult patients visit our specialised clinic each year,
of whom 23% are diagnosed with CRPS-1.18 This means
that in our clinic 30–40 patients are diagnosed with
CRPS-1 each year. To increase the amount of eligible
patients for our trial, we approached hospitals and
general practitioners in our region to help recruit poten-
tial participants.17 A rehabilitation physician (HvdM)
and a surgeon ( JPMF) performed physical examination
to determine whether patients were eligible and the
diagnosis of CRPS-1 could be conﬁrmed using the
research diagnostic criteria for CRPS as proposed by
Harden et al.19
Diagnostic CRPS criteria:
1. Continuing pain, which is disproportionate to any
inciting event
2. At least one symptom in each of the four following
categories:
– Sensory: reports of hyperalgesia and/or allodynia
– Vasomotor: reports of temperature asymmetry, skin
colour changes and/or skin colour asymmetry
– Sudomotor/oedema: reports of oedema, sweating
changes and/or sweating asymmetry
– Motor/trophic: reports of decreased range of
motion, motor dysfunction and/or trophic
changes
3. At least one sign in two or more of the following
categories:
– Sensory: evidence of hyperalgesia and/or allodynia
– Vasomotor: evidence of temperature asymmetry
(>1°C), skin colour changes and/or skin colour
asymmetry
– Sudomotor/oedema: evidence of oedema, sweat-
ing changes and/or sweating asymmetry
– Motor/trophic: evidence of decreased range of
motion, motor dysfunction and/or trophic
changes
4. There is no other diagnosis that better explains the
signs and symptoms.
Other inclusion criteria were that the ﬁrst assessment
took place between 3 and 24 months after the inciting
event and patients were between 18 and 80 years of age.
In case of other causes for the signs and symptoms (eg,
non-union, osteomyelitis and CPRS-2), patients were
excluded ( JPMF and HvdM). The exclusion criteria
included CRPS-1 in more than one extremity, relapse of
CRPS-1, pregnancy, lactation and prior sympathectomy
of the affected extremity.
The trial lasted from 9 January 2009 to 7 March 2012.
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Blinding
The trained research nurse (TT) who performed all
assessments prior to randomisation and during follow-up
was blinded to the treatment allocation. Given the
nature of the interventions, it was not possible to blind
the patients and the therapists, although both treatment
teams did not have contact with each other. Patients
were instructed not to discuss their treatment with the
research nurse.
Randomisation and interventions
A statistician who had no clinical involvement in the
trial (HG) designed a computerised randomisation
program. An independent person (MR) allocated
patients to one of the two treatment groups (PEPT or
conventional treatment (CONV), table 1) in a 1:1 ratio
using the randomisation program. The researcher
( JPMF) who determined the eligibility of patients was
unaware of the randomisation sequence.
Pain exposure physical therapy
PEPT was conducted by two physical therapists together
(FPK and AP, FPK and MT), who were trained by a
psychologist to actively interact with the patient and his
or her partner during the treatment sessions. PEPT con-
sisted of a maximum of ﬁve treatment sessions, each of
40 min duration, with varying intervals between the ses-
sions depending on the progression and personal needs
of the patient. Treatment was ceased when the patients
met their predeﬁned functional treatment goals, or
when they showed insufﬁcient motivation and self-
efﬁcacy, strong resistance or insufﬁcient results.14 15 17
Conventional treatment
A different group of physicians carried out CONV. This
treatment included pharmacological interventions
(RTMvD) combined with physical therapy in a more
pain-contingent manner (PPM, JO and RTMvD).8
The physician carrying out the pharmacological inter-
vention was based at a remote location of our university
hospital.
Treatment compliance and adverse events
We measured treatment compliance by documenting
the attendance to physical therapy (either PEPT or
CONV) and to the physician, and reporting use of medi-
cation. During each visit, abidance to treatment was
checked. Side effects were documented in the patient’s
medical record. We used standardised serious adverse
event forms for reporting (serious) adverse events.
Outcomes
The primary outcome measure was the Impairment level
Sum Score—Restricted Version (ISS-RV), which consists
of three measurement parameters focusing on typical
signs and symptoms of CRPS-1 (pain, active range of
motion (AROM) and temperature). ISS-RV contains
four measurement instruments: visual analogue scale for
pain (VAS-pain),20 McGill Pain Questionnaire Dutch
Language Version (MPQ-DLV),21 AROM of joints22 and
skin temperature.23 Each element of ISS-RV is converted
to a 1–10 points scale, which results in a sum score
ranging from 4 to 40 points.24–26 A higher value refers
to a more severe impairment. We consider a difference
of four ISS-RV points as clinically relevant.27
We based the secondary outcome measures on the
WHO International Classiﬁcation of Functioning,
Disability and Health.28 We included:
1. The Pain Disability Index29 (PDI) to measure disabil-
ity and the level of activities;
2. Muscle strength30 to measure functioning (grip
strength for the upper extremity and strength of dor-
siﬂexors and plantar ﬂexors of the ankle for the
lower extremity);
3. Short Form 36 (SF-36) Questionnaire31 to measure
the level of participation;
4. Disability of the arm, shoulder and hand, DLV
(DASH-DLV) questionnaire32 to measure activities
involving the upper extremity;
5. Lower Limb Tasks Questionnaire (LLTQ);33
6. 10-metre walk test (10MWT);34–36
7. Timed up-and-go test (TUG)36–39 to measure activ-
ities related to the lower extremity;
8. Quality of life, using the EuroQol-5D (EQ-5D) index
and VAS.40
We also asked patients how well they could perform
the physical therapy.
The cost-effectiveness analysis and analysis of psycho-
logical outcome measures (eg, Pain Catastrophising
Scale) are ongoing and we will present them in subse-
quent publications.
Sample size calculation
The sample size calculation was based on an expected
proportion of responders of 80% in the PEPT group14
and 50% in the CONV group.27 Given an α of 0.05 and
a power of 80% for a one-sided χ2 test, 62 patients had
to be included when using a 1:1 randomisation.
Statistical analysis
KJB and HG assembled all measured data in a database
and analysed them using SPSS V.20.0 for Windows (SPSS
Inc, Chicago, Illinois, USA). Baseline characteristics of
the patients and baseline values of the outcome mea-
sures were described using measures of central tendency
and dispersion. We conducted the statistical analysis
following the intention-to-treat principle (ITT): patients
were analysed in the groups to which they were allo-
cated. We also performed a secondary analysis following
the per protocol (PP) principle: only the patients who
followed the randomisation protocol were analysed and
the patients who opted out of the treatment allocation
prior to treatment initiation were excluded from this
analysis. We performed a responder analysis in order to
compare the proportion of patients achieving the
minimal clinically important difference (MCID) of four
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points on ISS-RV. We used linear mixed models with
unstructured repeated covariance to determine the
between-group differences over time. Treatment, meas-
urement in time, and treatment×time interaction were
added to the model as factors and outcome at baseline
was added as a covariate. Linear mixed models deal with
missing data by predicting the best-ﬁtting line for each
patient without data imputation.
Role of the funding source
The Netherlands Organisation for Health Research and
Development (ZonMw; 1709901004) sponsored this
study. The sponsor had no role in the study design, data
collection, data analysis, data interpretation or writing of
the report.
RESULTS
Study participants
Between January 2009 and June 2011, 432 patients were
referred to the CRPS outpatient department of our hos-
pital. Of these patients, 328 (75.9%) were CRPS negative
and another 30 did not meet the remaining inclusion
criteria. Seventy-four patients fulﬁlled the study inclu-
sion criteria and were invited to participate in the study.
Eighteen patients did not give their informed consent
due to constraints like travel time or an unwillingness to
undergo frequent assessments. The resulting 56 patients
were randomly allocated to either PEPT (n=28) or
CONV (n=28). Prior to treatment initiation, four
patients (14%) in the PEPT group and 11 patients
(39%) in the CONV group opted out of their assigned
treatment and switched groups.
Figure 1 shows the participant ﬂow. During the course
of the trial, three additional patients switched from CONV
to PEPT due to insufﬁcient results with their treatment.
One patient in the PEPT group dropped out after two
treatment sessions because of complete recovery. One
patient in the CONV group was not conﬁdent about the
treatment and was lost to follow-up. Another patient in
the CONV group stopped without offering a reason.
Table 2 shows the baseline characteristics of the
groups. The baseline values of the primary and second-
ary outcome measures are shown in the ﬁrst columns of
tables 3 and 4, respectively.
Six patients in the PEPT group received analgesics
from their general practitioner, but it was unclear
whether this was CRPS related. One patient received
DMSO and amitriptyline 10 mg, one patient received
Arthrotec (diclofenac 50 mg/misoprostol 200 µg and
diclofenac 75 mg/misoprostol 200 µg), one received
paracetamol/codeine phosphate (500/10 mg), one
received ibuprofen (600 mg) and omeprazol (20 mg),
one received diclofenac (50 mg) for 1 month and one
patient received Zaldiar (tramadol 37.5 mg/paracetamol
325 mg) for 10 days. Two patients in the PEPT group
received some form of CONV. Two patients who were
allocated to the CONV group and switched to PEPT
prior to treatment initiation also received some form of
CONV; one patient received DMSO, oxynorm, ondanse-
tron, oxycontin, lyrica and primperan; one patient
received diclofenac, transcutaneous electrical nerve
stimulation and standard physical therapy.
All other patients received their treatment according
to the methods described in the intervention section.
None of the patients received spinal cord stimulation or
sympathetic blockade.
Figure 1 Trial profile (CONV,
conventional treatment; ITT,
intention-to-treat; PP, per
protocol; PEPT, pain exposure
physical therapy).
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Outcomes
Table 3 shows the values at all measurement points of
ISS-RV and its constituents. The values of the secondary
outcome measures are shown in table 4. Table 5 displays
the estimated group differences for both the ITT analysis
and the PP analysis. The factor treatment×time inter-
action was not signiﬁcant, and we therefore left it out of
the linear mixed models.
In the PEPT group, 63% of the patients achieved
the MCID, compared to 56% in the CONV group,
with a risk ratio of 1.12 (95% CI 0.72 to 1.77). A
responder analysis showed no signiﬁcant association
between treatment and achieving the MCID: χ2 (1)
=0.26, p=0.41.
The ITT analysis showed a decrease in ISS-RV of 6.7
points for the PEPT group and 6.2 points for the CONV
group (estimated group difference 0.96, 95% CI −1.56
to 3.48; p=0.45) over 9 months (ﬁgure 2). The AROM
showed a signiﬁcant difference between groups with a
decrease of 1.8 points in the PEPT group and 1.6 points
in the CONV group (0.51, 95% CI 0.07 to 0.94; p=0.02).
VAS-pain, MPQ and skin temperature, as well as the sec-
ondary outcome measures, showed improvement over
time, but there were no signiﬁcant between-group differ-
ences in the ITT analysis.
The PP analysis showed greater improvement and dif-
ferences between treatment groups in favour of PEPT, as
shown in table 5. The PP estimated between-group dif-
ferences in ISS-RV was 2.90 (95% CI 0.10 to 5.70;
p=0.04), VAS-pain decreased 1.61 points more in the
PEPT group than in the CONV group (95% CI 0.06 to
3.16; p=0.04) and the difference in AROM between the
groups was 0.75 points (95% CI 0.28 to 1.23; p=0.003).
According to the PP analysis, patients in the PEPT
group also had a signiﬁcantly larger improvement in
PDI, SF-36, LLTQ and TUG. The other outcome mea-
sures improved over time for both treatment groups, but
between-group differences were not signiﬁcant.
Most of the treatment effects were reached at
3 months after inclusion and remained over time.
Patients in the PEPT group had a mean of four treat-
ment sessions, whereas patients in the CONV group
visited their physical therapists 17 times on average. The
physical therapy was feasible for 75.0% of the patients in
the PEPT group compared to 72.7% of patients in the
CONV group.
Table 2 Baseline characteristics of participants
Overall Intention-to-treat Per protocol
Variable (n=56) PEPT (n=28) CONV (n=28) PEPT (n=24) CONV (n=17)
Age (years)* 44.3 (16.6) 43.7 (14.8) 44.9 (18.5) 43.1 (15.6) 46.1 (17.9)
Women (n) 45 (80.4%) 24 (85.7%) 21 (75.0%) 20 (83.3%) 12 (70.6%)
Upper extremity (n) 37 (66.1%) 18 (64.3%) 19 (67.9%) 15 (62.5%) 14 (82.4%)
Dominant side affected (n) 32 (57.1%) 13 (46.4%) 19 (67.9%) 12 (50.0%) 14 (82.4%)
Time since event (months)* 7.2 (4.1) 7.0 (3.8) 7.5 (4.5) 7.0 (4.0) 8.1 (4.9)
*Mean (SD).
CONV, conventional treatment; PEPT, pain exposure physical therapy.
Table 3 Descriptives of the primary outcome measures for the intention-to-treat analysis
Variable Baseline 3 months 6 months 9 months
ISS-RV (range 4–40)*
PEPT 21.00 (5.30) 14.94 (5.84) 14.86 (6.13) 14.30 (5.88)
CONV 21.12 (5.31) 16.43 (6.25) 15.03 (6.35) 14.92 (5.28)
VAS-pain (range 1–10)*
PEPT 6.18 (2.50) 4.41 (2.85) 4.31 (2.81) 3.52 (2.69)
CONV 7.11 (2.01) 5.35 (3.09) 4.92 (3.34) 4.96 (3.02)
McGill Pain Questionnaire (range 1–10)*
PEPT 5.73 (2.11) 4.33 (1.97) 3.78 (2.30) 3.60 (1.70)
CONV 5.15 (1.43) 4.36 (1.91) 3.90 (2.05) 3.29 (1.88)
Active range of motion (range 1–10)*
PEPT 4.71 (2.16) 3.11 (1.26) 3.35 (1.67) 2.89 (1.22)
CONV 4.93 (1.98) 4.04 (1.95) 3.52 (1.26) 3.32 (0.95)
Skin temperature (range 1–10)*
PEPT 4.39 (2.91) 3.07 (2.39) 3.50 (2.52) 4.26 (3.15)
CONV 3.96 (3.35) 2.92 (2.74) 3.00 (2.23) 3.32 (2.45)
Data are based on raw data; mean (SD).
*A decrease means improvement.
CONV, conventional treatment; ISS-RV, Impairment level Sum Score—Restricted Version; PEPT, pain exposure physical therapy; VAS, visual
analogue scale.
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Adverse events
None of the patients reported serious adverse events or
disease deterioration. In the CONV group, several
patients reported drug-related side effects (nausea, con-
stipation), but these were managed by temporarily redu-
cing the dose or changing medication.
DISCUSSION
Statement of principal findings
With the results of this ﬁrst randomised controlled,
single-blinded trial on PEPT, we cannot state that PEPT
is superior to CONV for patients with CRPS-1. Patients
in both treatment groups experienced a clinically
important decrease in ISS-RV, but we did not ﬁnd a sig-
niﬁcant between-group difference. We did observe a sig-
niﬁcantly larger improvement of AROM for patients
treated with PEPT. The ITT analysis showed no other dif-
ferences between treatment groups. The PP analysis
showed larger and signiﬁcant between-group effects on
ISS-RV, VAS-pain, AROM, PDI, SF-36, LLTQ and TUG.
Meaning of the study
Both groups improved substantially on ISS-RV (6.7
points for the PEPT group and 6.2 points for the CONV
group), although there was no signiﬁcant between-group
difference. We also observed a relevant improvement in
disability for both groups, which we also consider an
important outcome measure.
This study indicates that CRPS-1 may be treated with
well-tolerated PEPT, without the use of medication, thus
avoiding adverse effects and high costs of medication.
However, owing to certain shortcomings in the execu-
tion of this trial, as mentioned hereafter in the discus-
sion, while the within-group differences for both
treatments suggest improvement, the between-group dif-
ferences do not provide evidence that PEPT offers add-
itional beneﬁt over CONV. This could be relevant for a
cost-effectiveness analysis. Because of the maximum dur-
ation of ﬁve treatment sessions, PEPT is a low-cost inter-
vention: the number of physical therapy sessions in
CONV was much higher than that with PEPT.17 The
Table 4 Descriptives of the secondary outcome measures for the intention-to-treat analysis
Variable Baseline 3 months 6 months 9 months
Pain Disability Index (range 0–70)*
PEPT 36.08 (11.38) 22.88 (14.44) 14.33 (14.37) 14.49 (14.80)
CONV 34.12 (14.59) 22.92 (15.91) 18.37 (14.49) 15.94 (15.34)
Muscle strength (%)*†
PEPT 61.90 (22.96) 36.80 (27.86) 27.50 (26.52) 25.83 (27.39)
CONV 67.14 (23.16) 46.10 (26.16) 38.25 (27.20) 32.50 (27.22)
SF-36 (range 0–100)‡
PEPT 48.17 (15.31) 60.90 (17.55) 73.98 (13.63) 73.30 (17.49)
CONV 47.60 (16.85) 58.35 (20.73) 66.39 (17.42) 68.57 (18.90)
DASH (range 0–100)*§
PEPT (n=18) 57.33 (13.54) 37.00 (17.70) 28.79 (19.88) 28.57 (19.88)
CONV (n=19) 58.27 (12.18) 43.45 (22.91) 35.59 (21.19) 27.52 (22.00)
LLTQ daily activity (range 0–40)‡¶**
PEPT (n=9) 17.33 (8.12) 24.75 (4.80) 32.84 (5.02) 36.71 (3.90)
CONV (n=7) 15.14 (8.45) 22.00 (10.53) 23.70 (11.08) 25.79 (11.92)
10MWT (in s)*¶
PEPT (n=10) 35.78 (39.19) 15.84 (2.23) 15.33 (4.37) 16.16 (8.25)
CONV (n=9) 62.86 (58.37) 75.50 (147.29) 25.22 (16.48) 20.17 (10.73)
TUG (in s)*¶
PEPT (n=10) 11.78 (8.51) 36.03 (94.20) 6.12 (1.51) 6.47 (2.87)
CONV (n=9) 22.40 (25.04) 22.40 (37.94) 9.65 (4.67) 7.66 (2.62)
EQ-5D index (maximum 1)‡
PEPT 0.53 (0.26) 0.63 (0.22) 0.77 (0.19) 0.76 (0.20)
CONV 0.47 (0.29) 0.64 (0.26) 0.67 (0.32) 0.74 (0.25)
EQ-5D VAS (range 0–100)‡
PEPT 64.42 (15.71) 69.88 (18.56) 74.75 (16.11) 75.80 (14.27)
CONV 61.48 (17.20) 69.42 (21.22) 70.96 (20.46) 75.46 (14.60)
Data are based on raw data; mean (SD).
*A decrease means improvement.
†Muscle strength (%)=left-right difference, relative to the non-affected side.
‡An increase means improvement.
§Only for participants with upper extremity affected.
¶Only for participants with lower extremity affected.
**Not all participants completed all assessments at all time points.
10MWT, 10-metre walk test; CONV, conventional treatment; DASH, disability of arm, shoulder and hand; EQ-5D, EuroQol-5D; LLTQ, Lower
Limb Tasks Questionnaire; PEPT, pain exposure physical therapy; SF-36, Short Form 36; TUG, timed up-and-go test; VAS, visual analogue
scale.
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outcomes of a cost-effectiveness analysis will be pub-
lished in a subsequent paper, but based on the previous
statements it seems that, from an economic point of
view, PEPT could be recommended to patients as well as
by caregivers and health insurance companies.
The effects reported in table 5 are estimated effects.
We did not include a treatment × time interaction to the
analysis, as this did not contribute to the model. The dif-
ference in outcome between treatments was achieved
after 3 months (T1) and remained stable over time.
Strengths and limitations of the study
Our trial included a number of aspects to minimise bias.
We prospectively registered the trial and followed the
published protocol.17 Patients were randomised, alloca-
tion was concealed and the assessor was blinded,
although we did not systematically record whether
patients unblinded the assessor. Small groups of cor-
rectly instructed therapists conducted the treatments at
different locations of our university hospital. The thera-
pists applying the experimental treatment were speciﬁc-
ally trained to perform PEPT. The physical therapists
who applied CONV were the same therapists as those
applying treatments in the studies by Oerlemans et al.41
A homogeneous group of patients was included, with
baseline characteristics comparable to those of the
normal patient population. This argues for generalisabil-
ity of our ﬁndings in the population. However, we only
included patients with one affected extremity, so we
cannot draw conclusions about the effect of PEPT for
patients with more than one affected extremity.
Furthermore, the median duration of symptoms was
relatively short (6.0 months, IQR 4–9) and only 12.5%
of patients reported at our outpatient clinic ≥12 months
after the inciting event. Therefore, we cannot generalise
the results of this study to chronic patients.
The inclusion rate was disappointing and the maximum
duration of the study forced us to accept a lower number
of participants than was calculated for the optimal sample
size. No speciﬁc measures were undertaken to compensate
for non-compliance or loss-to-follow-up and after random-
isation, a substantial number of patients (15/56; 26.8%)
opted out of their assigned treatment and did not follow
the trial protocol. As a result, this trial was underpowered
and the primary analysis was based on mixed groups; thus,
the actual effect was diluted. These are important limita-
tions of our trial.
We could not foresee so many patients changing treat-
ment group before having ﬁnished the initial allocated
treatment. Since the initial inclusion rate was low, the
funding organisation allowed us to take 1 year extra but
without extra ﬁnancial support. Owing to ﬁnancial lim-
itations, we could not afford to exceed the extra inclu-
sion period.
Our hospital is known for its research on CRPS-1, and
patients referred to our hospital might have had the
expectation to receive a new treatment. The larger
number of patients that switched to the PEPT group dir-
ectly after randomisation might be due to this expect-
ation. However, we did not evaluate possible preferences
Table 5 Estimated differences between treatment groups based on linear mixed models for both intention-to-treat and PP
analyses
Variable
ITT estimated
difference (95% CI) p Value
PP estimated
difference (95% CI) p Value
ISS-RV 0.96 (−1.56 to 3.48) 0.45 2.90 (0.10 to 5.70) 0.04
VAS-pain 0.61 (−0.70 to 1.92) 0.36 1.61 (0.06 to 3.16) 0.04
McGill Pain Questionnaire 0.01 (−0.83 to 0.85) 0.99 0.06 (−0.84 to 0.95) 0.89
Active range of motion 0.51 (0.07 to 0.94)* 0.02 0.75 (0.28 to 1.23) 0.003
Skin temperature −0.52 (−1.53 to 0.50) 0.31 0.30 (−0.72 to 1.33) 0.55
Pain Disability Index 4.98 (−1.32 to 11.28) 0.12 7.91 (1.06 to 14.76) 0.03
Muscle strength† 6.42 (−4.65 to 17.48) 0.25 12.64 (−0.40 to 25.68) 0.06
SF-36 overall mean −4.74 (−11.85 to 2.36) 0.19 −6.64 (−13.19 to −0.08)‡ 0.05
DASH 6.47 (−5.97 to 18.90) 0.30 9.98 (−3.29 to 23.24) 0.13
LLTQ daily activity 5.11 (−0.45 to 10.68) 0.07 −22.04 (−28.78 to −15.29) <0.001
10MWT§ NA NA NA NA
TUG 1.14 (−1.77 to 4.05) 0.42 11.27 (8.11 to 14.43) <0.001
EQ-5D index −0.01 (−0.10 to 0.08) 0.79 −0.06 (−0.17 to 0.06) 0.33
EQ-5D VAS 2.41 (−4.69 to 9.50) 0.50 0.45 (−7.98 to 8.89) 0.91
Estimated between-group differences, based on linear mixed models with unstructured repeated covariance, where treatment and
measurement in time are factors in the model and outcome at baseline is a covariate. A between-group difference is defined as the score of
the conventional treatment group minus the score of the PEPT group.
*The mean improvement in active range of motion is 0.51 points greater in the PEPT group than in the conventional treatment group.
†Muscle strength (%)=left-right difference, relative to the non-affected side.
‡The mean improvement in SF-36 is 6.64 points greater in the PEPT group than in the conventional treatment group.
§Analyses with the 10MWT could not be performed due to lack of power.
10MWT, 10-metre walk test; DASH, disability of arm, shoulder and hand; EQ-5D, EuroQol-5D; ISS-RV, Impairment level Sum Score—
Restricted Version; ITT, intention-to-treat; LLTQ, Lower Limb Tasks Questionnaire; PP, per protocol; SF-36, Short Form 36; TUG, timed
up-and-go test; VAS, visual analogue scale.
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prior to randomisation. In future trials, we should
explore the opinions and expectations of the patients
better prior to inclusion and randomisation.
Furthermore, there should be better education about
the implication of randomisation in order to minimise
switching after inclusion.
A disadvantage of randomised controlled trials is that
some patients refrain from participation because of ran-
domisation; they do not want to risk being allocated to
the control intervention. Patients who do participate may
be disappointed when they are assigned to the control
group, which can result in dropouts or patients switching
to the experimental group.42 One might question
whether a conventional randomised controlled trial is the
most appropriate form of research in such cases.
After completion of this trial, a Cochrane review was
published, showing the lack of evidence of most CONV
modalities,7 making it difﬁcult to place the results of this
trial in perspective. A placebo-controlled trial would
reveal the actual treatment effect, without the risk of
switching or potentially biasing factors. However, it
seems rather undoable to conduct a placebo-controlled
physical therapy trial, given the nature of the treatment,
the intensity of the condition and the clear request for
help in most patients.
A relatively new type of study design, called cohort
multiple randomised controlled trial, tackles the afore-
mentioned problems regarding recruitment and alloca-
tion and might be a good alternative design in
populations like the one under study.43
Owing to switching of treatment groups, shifts in base-
line characteristics occurred for the PP analysis. The
CONV group contained more patients with an affected
upper extremity and the dominant side was affected
more often in this group. These differences, however,
were not signiﬁcant. According to adjusted analyses,
introducing these variables to the model had little inﬂu-
ence on the outcome and correction for the variables in
the analysis appeared to be unnecessary.
ISS is speciﬁcally developed for measuring severity of
CRPS-1. A disadvantage of this score is that continuous
data are converted to a 1 to 10 scale, which leads to loss
Figure 2 Outcomes of the Impairment level Sum Score—Restricted Version (ISS-RV) and its subscales, and the Pain Disability
Index. Data are based on raw data; mean (95% CI). Light lines, pain exposure physical therapy group. Dark lines, conventional
treatment group. (A) Primary outcome ISS-RV and its subscales, intention-to-treat. (B) Pain Disability Index, intention-to-treat. (C)
Primary outcome ISS-RV and its subscales, per protocol. (D) Pain Disability Index, per protocol (ISS-RV, Impairment level Sum
Score—Restricted Version; VAS, visual analogue scale).
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of data. However, ISS provides a balanced score, in
which all domains are represented equally. Since several
trials have used ISS as an outcome measure, this allows
for comparison of results between trials. In ISS-RV, meas-
urement of limb volume is excluded. This is a rather
irreproducible measure with low sensitivity, and causes
increased variability in the ISS scores, rendering it less
useful.24 We expect that excluding measurement of limb
volume will not affect the reliability of the sum score.
In the study protocol of this trial, we mentioned three
other secondary outcome measures (PAR, the Seven
Days Physical Activity Recall questionnaire; IPAQ, the
International Physical Activity questionnaire; and
Personal Activity Monitor, an accelerometer). However,
data sets of the outcomes were too incomplete and
therefore unsuitable for analysis.
Not all patients who were treated with PEPT adhered
to the treatment protocol: 10 patients received some
form of medication or other CONV. Most of this treat-
ment was prescribed by their general practitioners, who
were not involved in the trial, and in some cases it was
not clear whether the treatment was CRPS related.
Strengths and limitations in relation to other studies
Ek et al studied PEPT in a cohort of 106 adult patients
with long-lasting CRPS-1. Function improved in 90% of
patients, and they observed full functional recovery in
46% of patients.14 In 2011, we published an article on
the safety of PEPT, reporting that we did not observe
exacerbations of CRPS-1 symptoms during intensive
stress-loading exercises. A second remarkable ﬁnding
was that pain relief and complete remission of CRPS-1
symptoms could be reached without speciﬁc CRPS-1
medication and/or other invasive treatments.15
This study also showed decreased pain intensity,
increased AROM and decreased disability in the PEPT
group, without disease deterioration.
In another publication, we showed the results of a
mediation analysis on pain-related fears (fear-avoidance
beliefs, pain catastrophising and kinesiophobia) in the
treatment of CRPS-1 with PEPT. We found no indication
that pain-related fears mediate the reduction of disability
and pain.
Unanswered questions and future research
In this study, we observed no deterioration shortly after
ﬁnishing PEPT; however, future studies should explore
the long-term tenability of PEPT.
Future research should also focus on the question
whether PEPT is applicable to all patients with CRPS-1,
both acute and chronic, and whether psychological or
cognitive factors or differences in physical characteristics
need to be taken into account. Detection of and insights
into these factors would help us when making decisions
about an appropriate individual intervention.
In future studies, perhaps especially with (chronic)
pain patients, researchers should be attentive to expecta-
tions of potential participants in order to preclude a
large number of participants from switching treatment
groups.
CONCLUSION
We cannot state that PEPT is superior to CONV for
patients with CRPS-1. However, patients allocated to
PEPT did experience a greater improvement in AROM
compared to those allocated to CONV. In the ITT ana-
lysis, all other outcomes showed improvement over time,
but we were not able to detect signiﬁcant between-group
differences. The improvement in the PEPT group was
achieved in a maximum of ﬁve treatment sessions and
without the use of medication.
Interested readers can ﬁnd full details of the trial
protocol in the Supplemental Appendix, available with
the full text of this article, and at http://www.
biomedcentral.com/1471-2474/13/58.
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